Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.05)
# 3,570
Out of 4,732 analysts
79
Total ratings
31.17%
Success rate
-19.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $22.18 | - | 2 | Jan 13, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.74 | - | 6 | Dec 18, 2024 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $7.26 | - | 10 | Dec 9, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $1.15 | - | 7 | Nov 19, 2024 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $170 | $128.13 | +32.68% | 15 | Nov 15, 2024 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $14.03 | - | 4 | Oct 7, 2024 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $18.05 | - | 4 | Sep 9, 2024 | |
| YMAB Y-mAbs Therapeutics | Reiterates: Overweight | $20 | $6.16 | +224.68% | 2 | Sep 9, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Overweight | n/a | $13.34 | - | 5 | Sep 9, 2024 | |
| CRIS Curis | Reiterates: Overweight | n/a | $3.29 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.15 | - | 5 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.01 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.06 | +183.02% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $4.10 | +5,265.85% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.27 | +293.70% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 | $0.21 | +17,665.31% | 2 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.47 | +1,438.46% | 1 | Aug 12, 2022 |
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.18
Upside: -
ALX Oncology Holdings
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.74
Upside: -
Kura Oncology
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.26
Upside: -
Affimed
Nov 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.15
Upside: -
Ascendis Pharma
Nov 15, 2024
Reiterates: Overweight
Price Target: $170
Current: $128.13
Upside: +32.68%
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.03
Upside: -
Arvinas
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.05
Upside: -
Y-mAbs Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $6.16
Upside: +224.68%
Bicycle Therapeutics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.34
Upside: -
Curis
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.29
Upside: -
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.15
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.01
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.06
Upside: +183.02%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $4.10
Upside: +5,265.85%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.27
Upside: +293.70%
Sep 7, 2023
Reiterates: Overweight
Price Target: $38
Current: $0.21
Upside: +17,665.31%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.47
Upside: +1,438.46%